TDOC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Teladoc Health Inc (TDOC) is not a strong buy at this time for a beginner investor with a long-term horizon. The company's financial performance shows declining profitability, and there are no significant positive catalysts or trading signals to support a buy decision. Analysts' ratings and price targets are mixed, with a cautious outlook. While options data indicates bullish sentiment, it is not enough to outweigh the company's weak financials and lack of recent positive news.
The MACD is positive but contracting, RSI is neutral at 51.2, and moving averages are converging, indicating no clear trend. Key support and resistance levels are Pivot: 5.614, R1: 6.099, S1: 5.129. The stock is trading near its pivot point, suggesting limited immediate upside.
Deutsche Bank and BofA recently upgraded the stock with price targets of $11 and $8.25, citing undervaluation and potential growth in the BetterHelp business. The stock is also trading at a low price, which could attract value investors.
The company is transitioning its business model in a competitive market, which adds uncertainty. Financial performance in Q4 2025 showed declining net income (-48.06% YoY) and EPS (-50.00% YoY). Analysts have lowered price targets multiple times, reflecting cautious sentiment.
In Q4 2025, revenue increased marginally by 0.28% YoY to $642.27M. However, net income dropped significantly by 48.06% YoY to -$25.14M, and EPS fell by 50.00% YoY to -$0.14. Gross margin also declined to 54.55%, down 3.50% YoY, indicating weaker profitability.
Analysts' ratings are mixed. Deutsche Bank and BofA have Buy ratings with higher price targets, while others like Barclays, Citi, and UBS maintain Neutral ratings with lower price targets. The consensus reflects cautious optimism but no strong conviction for a buy.
